Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $1.9 million.

  • Stoke Therapeutics' Other Non-Current Liabilities fell 3855.74% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 3855.74%. This contributed to the annual value of $2.5 million for FY2024, which is 4926.29% down from last year.
  • Per Stoke Therapeutics' latest filing, its Other Non-Current Liabilities stood at $1.9 million for Q3 2025, which was down 3855.74% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Other Non-Current Liabilities registered a high of $4.9 million during Q4 2023, and its lowest value of $959000.0 during Q3 2023.
  • Over the past 4 years, Stoke Therapeutics' median Other Non-Current Liabilities value was $3.0 million (recorded in 2022), while the average stood at $2.8 million.
  • Per our database at Business Quant, Stoke Therapeutics' Other Non-Current Liabilities crashed by 7343.49% in 2023 and then soared by 21803.96% in 2024.
  • Stoke Therapeutics' Other Non-Current Liabilities (Quarter) stood at $3.0 million in 2022, then surged by 64.56% to $4.9 million in 2023, then crashed by 49.26% to $2.5 million in 2024, then fell by 24.37% to $1.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.9 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.9 million for Q1 2025.